Steroid 5α-reductase inhibitors in androgen-dependent disorders

Current Opinion in Chemical Biology

Volumn 1, Issue 2, 1997, Pages 254-259

  Harris, Georgianna S ^a   Kozarich, John W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE;

ACNE VULGARIS; ALOPECIA; CHEMISTRY; DRUG ANTAGONISM; HUMAN; MALE; PHYSIOLOGY; PROSTATE HYPERTROPHY; REVIEW;

ACNE VULGARIS; ALOPECIA; ANDROGENS; ENZYME INHIBITORS; HUMANS; MALE; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0031197126     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80017-8     Document Type: Article

References (54)

1. Wilson JD, Griffin JE, Russell DW: Steroid 5α-reductase 2 deficiency. Endocrin Rev 1993, 14:577-593.
2. Russell DW, Wilson JD: Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 1994, 63:25-61.
3. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE: Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974, 27:1213-1215.
4. Peterson RE, Imperato-McGinley J, Gautier T, Sturla E: Male pseudohermaphroditism due to steroid 5α-reductase deficiency. Am J Med 1977, 62:170-191.
5. Fratianni CM, Imperato-McGinley J: The syndrome of 5α-reductase deficiency. Endocrinologist 1994, 4:302-314.
6. Imperato-McGinley J, Gautier T: Inherited 5α-reductase deficiency in man. Trends Genet 1986, 2:130-133.
7. Frye SV: Inhibitors of 5α-reductase. Curr Pharm Des 1996, 2:59-84. This comprehensive review provides a description of the historical development of inhibitors of 5αR and an extensive discussion of the structure-activity relationships of steroidal and nonsteroidal inhibitors of this enzyme.
8. Kenny B, Ballard S, Blagg S, Fox D: Pharmacological options in the treatment of benign prostatic hyperplasia. J Med Chem 1997, 40:1293-1315.
9. Levy MA, Brandt J, Greway AT: Mechanistic studies with solubilized rat liver steroid 5α-reductase: elucidation of the kinetic mechanism. Biochemistry 1990, 29:2808-2815.
10. Levy MA, Brandt M, Sheedy KM, Dinh JT, Holt DA, Garrison LM, Bergsma DJ, Metcalf BW: Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5α-reductase isoform 2. J Steroid Biochem Mol Biol 1994, 48:197-206.
11. Tian G, Chen S-Y, Facchine KL, Prakash SR: Chemical mechanism of the covalent modification of 5α-reductases by finasteride as probed by secondary tritium isotope effects. J Am Chem Soc 1995, 117:2369-2370.
12. Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, Kadwell SH, Overton LK, Kost TA, Mook RA Jr, et al.: 17β-(N-tertbutylcarbamoyl)-4-aza-5α-androstan-1-en-3-one is an active site directed slow time-dependent inhibitor of human steroid 5α-reductase 1. Biochemistry 1994, 33:2291-2296.
13. Bull HG, Garcia-Calvo M, Andersson SA, Baginsky WF, Chan HK, Ellsworth D, Miller R, Stearns RA, Bakshi RK, Rasmusson GH et al.: Mechanism-based inhibition of human steroid 5α-reductase by finasteride: enzyme catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J Am Chem Soc 1996, 118:2359-2365. This paper provides compelling evidence that the mechanism of inhibition of the human 5αR by finasteride is intimately related to catalysis. A mechanism of inhibition is proposed whereby finasteride is processed by the enzyme as an alternate substrate and ultimately forms an adduct with NADP.
14. Bakshi RK, Rasmusson GH, Patel GF, Mosley RT, Chang B, Ellsworth K, Harris GS, Tolman RL: 4-aza-3-oxo-5α-androst-1-ene-17β-N-aryl-carboxamides as dual inhibitors of human type 1 and 2 steroid 5α-reductatses. Dramatic effect of N-aryl substituents on type 1 and 2 5α-reductase inhibitory potency. J Med Chem 1995, 38:3189-3192.
15. Tian G, Mook RA Jr, Moss ML, Frye SV: Mechanism of time-dependent inhibition of 5α-reductase by D1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand binding energies. Biochemistry 1995, 34:13433-13459.
16. Bakshi RK, Patel GF, Rasmusson GH, Baginsky WF, Cimis G, Ellsworth K, Chang B, Bull H, Tolman RL, Harris GS: 4,7β-dimethyl-4-azacholestan-3-one (MK386) and related 4-azasteroids as selective inhibitors of human type 1 5α-reductase. J Med Chem 1994, 37:3871-3874.
17. Ellsworth K, Azzolina B, Baginsky W, Bull HG, Chang B, Cimis G, Mitra S, Toney J, Bakshi RK, Rasmusson GR et al.: MK386: a potent selective inhibitor of the human type 1 5α-reductase. J Steroid Biochem Mol Biol 1996, 58:377-384.
18. Gormley GJ: Finasteride: a clinical review. Biomed Pharmacother 1995, 49:319-324.
19. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken B, Tenover JS et al.: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327:1185-1191.
20. Gormley GJ, Stoner E, Rittmaster RS, Gregg H, Thompson DL, Lasseter KG, Vlasses PH, Stein EA: Effects of finasteride (MK906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990, 70:1136-1141.
21. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E: Finasteride, an inhibitor of 5α-reductase suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992, 74:505-508.
22. Schwartz JI, Vanhecken A, Deschepper PJ, De Lepeleire I, Lasseter KC, Cooper Shamblen E, Winchell GA, Constanzer ML, Chavez CM et al.: Effect of MK-386, a novel inhibitor of type 1 5α-reductase, alone and in combination with finasteride, on serum DHT (dihydrotestosterone) concentrations in men. J Clin Endocrinol Metab 1996, 81:2942-2947. This manuscript presents clinical data demonstrating that inhibition of 5αR1 with MK-386 decreases serum and sebum DHT. Furthermore, it is reported that combined inhibition of 5αR1 with MK-386 and 5αR2 with finasteride drops circulating DHT to the limit of detection.
23. Stoner E: 5α-reductase inhibitors/finasteride. Prostate 1996, 6:82-87.
24. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawtey OW, Ford LG: Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995, 16:150-163.
25. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG et al.: Clinical development plan: Proscar. J Cell Biochem 1994, 20 (suppl):231-239.
26. Thompson IM, Coltman CA: Screening for prostate cancer: opportunities for prevention. Semin-Urol-Oncol. 1996, 14 (suppl 2):4-10.
27. Audet P, Nurcombe H, Lamb Y, Jorasky D, Lloyd-Davis K, Morris R: Effect of multiple doses of epristeride (E) a steroid 5α-reductase inhibitor on serum dihydrotestosterone in older male subjects. Clin Pharmacol Ther 1993, 53:231.
28. Hermann DJ, Davis IM, Wilson TH: Effects of GI198745 (GG745), a novel 5-alpha-reductase (5αR) inhibitor on dihydrotestosterone (DHT). Clin Pharmacol Ther 1996, 59:192. This abstract provides evidence that combined inhibition of 5αR1 and 5αR2 with a single agent leads to significantly greater decreases in serum DHT than is obtained with finasteride, a selective inhibitor of 5αR2.
29. Silver RI, Wiley EL, Davis DL, Thigpen AE, Guileyardo JM, McConnell JD, Russell DW: Cell type specific expression of steroid 5α-reductase 2. J Urol 1994, 152:438-442.
30. Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW, McConnell JD: Expression and regulation of steroid 5α-reductase 2 in prostate disease. J Urol 1994, 152:433-437.
31. Harris G, Azzolina B, Baginsky W, Cimis G, Rasmusson GH, Tolman RL, Raetz CRH, Ellsworth K: Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc Natl Acad Sci USA 1992, 89:10787-10791.
32. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, Nguyen HH, Moore EG, Tanaka WK: The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994, 79:703-706.
33. Kaufman KD: Clinical studies on the effects of oral finasteride, a type II 5α-reductase inhibitor, on scalp hair in men with male pattern baldness. In Hair Research for the Next Millennium. Edited by Van Neste DJ, Randall VA. Amsterdam: Elsevier; 1996:363-365.
34. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW: Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 1993, 92:903-910.
35. Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S: Activity of the type , 5α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 1995, 105:209-214.
36. Eichler W, Dreher M, Hoffmann R, Happle R, Aumuller G: Immunohistochemical evidence for differential distribution of 5α-reductase isoenzymes in human skin. Br J Dermatol 1995, 133:371-376.
37. Bayne EK, Flanagan J, Azzolina B, Einstein M, Mumford R, Ayala J, Chang B, Thiboutot D, Singer I, Harris GS: Immunolocalization of type 2 5α-reductase in human hair follicles [abstract]. J Invest Dermatol 1997, 108:681.
38. Hamilton JB: Male hormone substance: a prime factor in acne. J Endocrinol Metab 1941, 1:507-592.
39. Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P: The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993, 76:524-528.
40. Schwartz JI, Tanaka WK, Wang DZ, Ebel DL, Geissler LA, Dallob A, Hafkin B, Gertz BJ: MK-386, an inhibitor of 5-alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen. J Clin Endocrinol Metabol 1997, 82:1373-1377. These investigators demonstrate that a differential response is obtained in serum, sebum and semen DHT upon selective inhibition of 5αR1 or 5αR2 with MK-386 or finasteride, respectively. It is suggested that mainly 5αR1 contributes to sebum DHT, 5αR2 is important for semen DHT and both isozymes contribute to serum DHT.
41. Kuttenn F, Mowszowicz I, Schaison G, Mauvais-Javis P: Androgen production and skin metabolism in hirsutism. J Endocrinol 1977, 75:83-91.
42. Rittmaster RS: Clinical relevance of testosterone and dihydrotestosterone metabolism in women. Am J Med 1995, 98(suppl 1A):17S-21S.
43. Cusan L, Dupont A, Belanger A, Tremblay RR, Manhes G, Labrie F: Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990, 23:462-469.
44. Gilchrist VJ, Hecht BR: A practical approach to hirsutism. Am Fam Physician 1995, 52:1837-1844.
45. Tremblay RR: Treatment of hirsutism with sprionolactone. J Clin Endocrinol Metab 1986, 15:363-371.
46. Castello R, Tosi F, Perone G, Negri C, Muggeo M, Moghetti P: Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 1996, 66:734-740. In this manuscript the authors present evidence that treatment of hirsute women with finasteride for one year led to a significant improvement in hirsutism scores.
47. Moghetti P, Castello R, Magnani CM, Tosi F, Negri C, Armanini D, Bellotti G, Muggeo M: Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism. J Endocrinol Metab 1994, 79:1115-1121.
48. Gasperino J: Androgenic regulation of bone mass in women. Clin Orthop Rel Res 1995, 311:278-286.
49. Shimodaira K, Fujikawa H, Okura F, Shimizu Y, Saito H, Yanaihara T: Oteroblast cells (MG-63 and HOS) have aromatase and 5alpha-reductase activities. Biochem Mol Bio Intl 1996, 39:109-116.
50. Matzkin H, Chen J, Weisman Y, Goldray D, Pappas F, Jaccard N, Braf Z: Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol 1992, 37:432-436.
51. Tollin SR, Rosen HN, Zurowski K, Saltzman B, Zeind AJ, Berg S, Greenspan SL: Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia - a Clinical Research Center study. J Clin Endocrinol Metab 1996, 81:1031-1034.
52. Ehrmann DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Rev 1995, 16:322-353.
53. Agarwal SK, Judd HL, Magoffin DA: A mechanism of the suppression of estrogen production in polycystic ovary syndrome. J Clin Endocrinol Metabol 1996, 81:3686-3691.
54. Haning RC Jr, Tantravahi U, Zhao Q, Hackett RJ, Canick JA: 5α-reductase 1 and 2 expression and activity in human ovarian follicles, stroma and corpus luteum as compared to neonatal foreskin. J Steroid Biochem Mol Biol 1996, 59:199-204.